SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
185 hedge funds and large institutions have $862M invested in SANGAMO THERAPEUTICS INC in 2019 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 76 increasing their positions, 40 reducing their positions, and 31 closing their positions.
90% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 40
67% more call options, than puts
Call options by funds: $26.2M | Put options by funds: $15.7M
37% more capital invested
Capital invested by funds: $631M → $862M (+$231M)
4.75% more ownership
Funds ownership: 64.6% → 69.35% (+4.8%)
6% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 31
1% less funds holding
Funds holding: 187 → 185 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$71.5M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$38.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$17.6M |
| 4 |
BlackRock
New York
|
+$11.7M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$8.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$9.23M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.37M |
| 3 |
Renaissance Technologies
New York
|
-$2.96M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.07M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.91M |
SGMO Hedge Fund Activity: Q2 2019 in Review
185 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q2 2019, worth a combined $862M — up 37% from $631M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new SGMO positions and 31 closed out — a net gain of 2 holders — while 76 added to existing stakes and 40 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $71.5M. The largest seller was Invesco, cutting an estimated $9.23M.
- 185 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q2 2019, down from 187 in Q1 2019.
- Funds reported $862M of SANGAMO THERAPEUTICS INC stock for Q2 2019, up 37% quarter-over-quarter.
- 33 funds opened new SANGAMO THERAPEUTICS INC positions in Q2 2019 and 31 closed out, a net change of +2 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q2 2019 was Wellington Management Group, an estimated $71.5M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q2 2019 was Invesco, an estimated $9.23M sold.
Based on aggregated 13F filings for Q2 2019.